Background: Acute liver failure is still a life-threatening disease although it can be treated by liver transplantation. This study was conducted to assess the molecular adsorbent recycling system (MARS), which may bridge acute liver failure patients to liver transplantation.
Methods: Biochemical indexes and other clinical data were analyzed of 8 patients with acute liver failure, who had been treated by MARS for 34 times and subsequent Piggyback liver transplantation.
Results: After treatment with MARS, the levels of transaminase and total bilirubin decreased markedly, but coagulation function remained unimproved. All patients survived and discharged from the hospital.
Conclusion: MARS is effective in bridging patients with acute liver failure to liver transplantation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to "Comparative study of transcriptomic alterations in sepsis-induced acute liver injury: Deciphering the role of alternative splicing in mouse models" [Int. Immunopharmacol. 146 (2025) 113878].
Int Immunopharmacol
January 2025
Department of Emergency, Kashi Prefecture Second People's Hospital, Kashi 844000, Xinjiang, China; Department of Emergency, Shanghai Tenth People's Hospital, School of Medicine Tongji University, Shanghai 200072, China. Electronic address:
Warfarin-induced gastrointestinal bleeding with acute liver failure: A case report.
Medicine (Baltimore)
November 2024
Department of Pharmacy, The People's Hospital of Hezhou, Hezhou, China.
Rationale: Warfarin is the most commonly used drug in patients with mechanical valve replacement. Acute liver damage after warfarin is rare but potentially harmful. We present a case of warfarin-induced gastrointestinal bleeding with liver injury, pharmacy monitoring, and its therapy.
View Article and Find Full Text PDFResveratrol attenuates cyclophosphamide-induced hepatic apoptosis in association with the inhibition of oxidative stress and inflammation in a rat model of acute liver injury.
Tissue Cell
January 2025
Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Cyclophosphamide (CP) is an alkylating chemotherapy agent that induces liver toxicity by cross-linking DNA, causing cell apoptosis. While CP is effective in cancer treatment, its side effects on the liver are significant. Recent studies have indicated that antioxidants, such as resveratrol, may reduce these toxic effects.
View Article and Find Full Text PDFCD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease.
Hepatology
January 2025
Université Côte d'Azur, INSERM, U1065, C3M, Nice, France.
Background And Aims: Alcohol-related liver disease (ALD) is one of the leading causes of severe liver disease with limited pharmacological treatments for alcohol-related steatohepatitis (ASH). CD44, a glycoprotein mainly expressed in immune cells, has been implicated in multiple inflammatory diseases but has never been studied in the ALD context. We therefore studied its contribution to ASH development in mice and its expression in ALD patients.
View Article and Find Full Text PDFCognitive impairment caused by compromised hepatic ketogenesis is prevented by endurance exercise.
J Physiol
January 2025
Department of Nutrition and Exercise Physiology, University of Missouri-Columbia, Columbia, Missouri, USA.
Extensive research has demonstrated endurance exercise to be neuroprotective. Whether these neuroprotective benefits are mediated, in part, by hepatic ketone production remains unclear. To investigate the role of hepatic ketone production on brain health during exercise, healthy 6-month-old female rats underwent viral knockdown of the rate-limiting enzyme in the liver that catalyses the first reaction in ketogenesis: 3-hydroxymethylglutaryl-CoA synthase 2 (HMGCS2).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!